Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 12/2007

01-12-2007 | Letter

Comment on: Gale EAM (2007) To boldly go—or to go too boldly? The accelerator hypothesis revisited. Diabetologia 50:1571–1575—a reply to the editor

Author: T. J. Wilkin

Published in: Diabetologia | Issue 12/2007

Login to get access

Excerpt

To the Editor: The Editor’s erudite commentary [1] on the accelerator hypothesis and its impact on the classification of diabetes [2] points to where the hypothesis may be vulnerable, offers the opportunity for adjustment and sets an intellectual standard by which the hypothesis will stand or fall. The hypothesis is based on the construct of tempo [3], and envisages a hierarchy of genotypes that respond to insulin resistance with corresponding rates of beta cell loss. Accordingly, a rise in insulin resistance across a population would predict a leftward shift, resulting in younger age at onset and an increase in incidence, both fundamental tenets of the hypothesis because they spell acceleration. …
Literature
1.
Gale EAM (2007) To boldly go—or to go too boldly? The accelerator hypothesis revisited. Diabetologia 50:1571–1575PubMedCrossRef
2.
Wilkin TJ (2007) Changing perspectives in diabetes: their impact on its classification. Diabetologia 50:1587–1592PubMedCrossRef
3.
Wilkin TJ (2001) The accelerator hypothesis: weight gain as the missing link between type I and type ll diabetes. Diabetologia 44:914–922PubMedCrossRef
4.
Wilkin TJ (2007) The accelerator hypothesis cannot be tested using the type 2 diabetes gene, TCF7L2. Diabetologia 50:1780PubMedCrossRef
5.
Field SF, Howson JMM, Smyth DJ, Walker NM, Dunger DB, Todd JA (2007) Analysis of the type 2 diabetes gene, TCF7L2, in 13,795 type 1 diabetes cases and control subjects. Diabetologia 50:212–213PubMedCrossRef
6.
Field SF, Howson JMM, Walker NM, Dunger DB, Todd JA (2007) Analysis of the obesity gene FTO in 14,803 type 1 diabetes cases and controls. Diabetologia DOI 10.​1007/​s00125-007-0767-0
7.
Hawa MI, Bonfanti R, Valeri C, Delli Castelli M, Beyan H, Leslie RD (2005) No evidence for genetically determined alteration in insulin secretion or sensitivity predisposing to type 1 diabetes: a study of identical twins. Diabetes Care 28:1415–1418PubMedCrossRef
8.
Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC (2004) Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia 47:1661–1667PubMedCrossRef
9.
Diabetes Prevention Trial–Type 1 Diabetes Study Group (2002) Effects of insulin on relatives of patients with type 1 diabetes. N Engl J Med 346:1658–1691CrossRef
10.
The European Nicotinamide Diabetes Intervention Trial (ENDIT) Group (2002) A randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 363:925–931
11.
Dabelea D, D’Agostino RB, Mayer-Davis EJ et al (2006) Testing the accelerator hypothesis: body size, beta-cell function, and age at onset of type 1 (autoimmune) diabetes. Diabetes Care 29:290–294PubMedCrossRef
12.
Wilkin TJ (2006) Testing the accelerator hypothesis: body size, beta-cell function, and age at onset of type 1 (autoimmune) diabetes: response to Dabelea et al. Diabetes Care 29:1462–1463 (author reply 1463–1464)PubMedCrossRef
13.
Knowler WC, Barrett-Connor E, Fowler SE et al.; Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403PubMedCrossRef
Metadata
Title
Comment on: Gale EAM (2007) To boldly go—or to go too boldly? The accelerator hypothesis revisited. Diabetologia 50:1571–1575—a reply to the editor
Author
T. J. Wilkin
Publication date
01-12-2007
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 12/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-007-0829-3

Other articles of this Issue 12/2007

Diabetologia 12/2007 Go to the issue

Commentary

The enteroinsular axis may mediate the diabetogenic effects of TCF7L2 polymorphisms

Article

Early mortality in EURODIAB population-based cohorts of type 1 diabetes diagnosed in childhood since 1989

Article

Within-subject variability of measures of beta cell function derived from a 2 h OGTT: implications for research studies

Letter

Increased physical activity is a cornerstone in the prevention of type 2 diabetes in high-risk individuals. Reply to Laaksonen DE, Lindström J, Tuomilehto J, Uusitupa M [letter]

Article

Strong association between mitochondrial DNA copy number and lipogenesis in human white adipose tissue

Letter

Increased physical activity is a cornerstone in the prevention of type 2 diabetes in high-risk individuals
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits